Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gel-forming mucins, primarily Mucin-5AC (MUC5AC) and Mucin-5B (MUC5B), are large, heavily glycosylated proteins secreted by airway epithelial goblet cells and submucosal glands [1.1.3, 1.3.3]. These proteins polymerize via the formation of extracellular disulfide bonds between cysteine-rich domains, creating a complex, viscoelastic gel network essential for mucociliary clearance and protecting the lungs from pathogens and particulates [1.1.2, 1.1.4]. In chronic airway diseases like cystic fibrosis, asthma, and COPD, hypersecretion and oxidative stress lead to the formation of pathological, highly cross-linked mucus that is difficult to clear [1.1.1, 1.2.3]. Therapeutic strategies target these extracellular disulfide bonds using reducing agents (mucolytics) to break the polymers into smaller subunits, thereby reducing mucus viscosity and improving clearance [1.3.1, 1.1.5].
Reduction of intermolecular disulfide bonds through thiol-disulfide exchange, leading to the depolymerization of mucin networks and a subsequent decrease in mucus viscoelasticity [1.1.1, 1.3.1].
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mucin-5AC and Mucin-5B gel-forming proteins (MUC5AC/MUC5B).